Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced GI Malignancies
Status:
Not yet recruiting
Trial end date:
2024-06-19
Target enrollment:
Participant gender:
Summary
This is an open-label, prospective phase two basket trial assessing the efficacy of
ulixertinib in combination with hydroxychloroquine in patients with advanced gastrointestinal
malignancies. All patients enrolled must have a MAPK activating mutation to be deemed
eligible for trial participation. Each disease-based basket will open to enrollment in
two-stages. The opening of stage two will be dependent on the observed responses in the
patients enrolled in the first stage.